Peer-Reviewed Publications

    Modeling early initiation processes in smoking-induced lung adenocarcinomas

    Vuillaume, G.; Mueller, T.; Talikka, M.; Cheng, Y.; Diserens, G.; Peitsch, M. C.; Hoeng, J.; Tobin, F.
    Published
    Jun 6, 2011
    Link to publication
    Topic
    Summary

    Most cancer models focus on the growth and progression of a tumor once a neoplasm has first formed. This work focuses on building a mathematical model of the early initiation processes for the earliest neoplasm for lung adenocarcinomas induced by smoking. The biology was triaged to identify the key biological behaviors causing the phenotype transition from never-smoker lung cells to the earliest phenotype considered a neoplasm. The biology is then translated into a set of nonlinear ordinary differential equations (ODEs). Finally, constrained optimization is used to obtain a single set of model parameters that simultaneously provides a good fit to all the experimental data sets and accurately reproduce the key biological phenomena, without producing any unacceptable one.

    Related Publications

    Impact of cigarette smoke and Modified Risk Tobacco Products (MRTPs) on DNA methylation

    Pre-clinical Toxicology Systems Toxicology

    Quantitative proteomics analysis using 2D-PAGE to investigate the effects of cigarette smoke and aerosol of a prototypic modified risk tobacco product on the lung proteome in C57BL/6 mice

    Pre-clinical Toxicology Systems Toxicology

    Anatabine ameliorates intestinal inflammation and reduces the production of pro-inflammatory factors in a dextran sulfate sodium mouse model of colitis

    Pre-clinical Toxicology Systems Toxicology

    The response of human nasal and bronchial organotypic tissue cultures to repeated whole cigarette smoke exposure

    Pre-clinical Toxicology Systems Toxicology

    Mechanism of an indirect effect of aqueous cigarette smoke extract on the adhesion of monocytic cells to endothelial cells in an in vitro assay revealed by transcriptomics analysis

    Pre-clinical Toxicology Systems Toxicology

    In vitro systems toxicology-based assessment of the potential modified risk tobacco product CHTP 1.2 for vascular inflammation- and cytotoxicity-associated mechanisms promoting adhesion of monocytic cells to human coronary arterial endothelial cells

    Pre-clinical Toxicology Systems Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.